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The ongoing coronavirus disease (COVID-19) pan-demic is having an unprecedented impact on the 
worldwide population. Seroconversion for severe 
acute respiratory syndrome coronavirus 2 (SARS-
CoV-2) was described to occur 7–14 days after onset of 
symptoms, 100% within 19 days after clinical onset (1). 
Recent serologic data suggest that, in affected areas, 
SARS-CoV-2 infection had been acquired by more per-
sons than what could be extrapolated by PCR analysis 
of nasopharyngeal swab specimens (1–3).
Large studies reported seroprevalences of 1%–
6.9% (2). In February 2020, seroprevalence for 12 
blood donors in Lodi, Italy, a heavily affected zone, 
was as high as 23% (3). Studying high-risk persons, 
such as healthcare workers, could be relevant for im-
plementing preemptive and protective strategies. In 
Italy, 30,383 healthcare workers (of 253,619 confirmed 
cases; 12.0%) have been reported to be infected since 
the beginning of the pandemic (4).
Active healthcare workers (n = 7,457) from 
Azienda Sanitaria Locale Città di Torino public hos-
pitals and outpatient services (Turin, Italy) were 
invited by email and printed leaflets to participate 
in our study. During April 17–May 20, 2020, they 
underwent blood withdrawal. SARS-CoV-2 anti-
bodies were measured by using capillary electro-
phoresis and chemiluminescence immunoassay 
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We measured severe acute respiratory syndrome coro-
navirus 2 spike protein subunits S1/S2 antibodies by us-
ing capillary electrophoresis and a chemiluminescence 
immunoassay for 5,444 active healthcare workers in Ita-
ly. Seroprevalence was 6.9% and higher among partici-
pants having contact with patients. Seroconversion was 
not observed in 37/213 previously infected participants. 
targeting IgGs against S1/S2 regions of spike pro-
tein (LIAISON; DiaSorin, https://www.diasorin.
com). This assay has a sensitivity of 97.9% and a 
specificity of 98.5% and a 94.4% positive agreement 
with the plaque reduction neutralization test (5). 
SARS-CoV-2 IgG concentrations were expressed in 
arbitrary units/mL (AU/mL) and deemed negative 
if <12 AU/mL. Persons who had equivocal (12–15 
AU/mL) or positive (>15 AU/mL) results provided 
nasopharyngeal swab specimens for SARS-CoV-2 
RNA detection by using an in-house real-time re-
verse transcription PCR, according to Corman 
et al. (6).
Ethics approval was obtained, and all partici-
pants signed an informed consent form. Anonymous 
data were collected and analyzed by using SPSS Sta-
tistics version 26 (IBM, https://www.ibm.com) and 
described as number (%) or mean ± SD. Disease se-
verity information was not collected.
We tested 5,444 (73.0%) of 7,457 healthcare 
workers; 4,068 (74.7%) were women. Participants 
had a mean ± SD age of 49.4 ± 10.6 years. S1/S2 
SARS-CoV-2 antibodies were found in 377 (6.9%) 
participants; 176 (46.7%) had cured COVID-19, 146 
(38.7%) had contacts with COVID-19 patients, and 
55 (14.6%) had no known epidemiologic link. Sero-
prevalence was not significantly higher in men than 
in women (7.9% vs. 6.5%; p = 0.097 by χ2 test), and no 
differences were observed among age groups. Mean 
± SD IgG titer was 49.2 ± 39.5 AU/mL. IgG titers 
were higher in older participants (Pearson r = 0.227, 
p<0.001 and p = 0.001 by analysis of variance; Ap-
pendix Figure, https://wwwnc.cdc.gov/EID/
article/27/1/20-3027-App1.pdf) and in those previ-
ously given a diagnosis of COVID-19 (57.9 AU/mL 
vs. 41.6 AU/mL in those without a previous diagno-
sis; p<0.001 by t-test).
Detailed task information was available for 4,630 
participants. Seroprevalence was highest in laborato-
ry personnel (18/175, 10.3%), although numbers were 
small, followed by nurse assistants (44/520, 8.5%), 
nurses (150/1983, 7.6%), and doctors (55/755, 7.3%). 
A significantly higher seroprevalence was observed 
in healthcare workers working in close contact with 
patients versus those with limited/indirect contacts 
(7.5% vs. 5.2%; p = 0.013 by χ2 test; odds ratio 1.464, 
95% CI 1.077–1.992) (Figure).
Among persons who had a previously diagnosed 
SARS-CoV-2 infection, 176 (82.6%) had S1/S2 SARS-
CoV-2 antibodies. Participants without S1/S2 SARS-
CoV-2 antibodies were younger (41.4 vs. 49.1 years; 
p<0.001) and had a shorter time since diagnosis (36 
vs. 44 days; p = 0.008). When we excluded persons 
who previously had COVID-19, all serology-positive 
participants (n = 201) provided a nasopharyngeal 
swab specimen for detection of SARS-CoV-2 RNA; 7 
(3.5%) were positive.
We found that SARS-CoV-2 infection had been 
acquired by 6.9% of healthcare workers in Torino, 
Italy. Variable seroprevalence has been described 
among healthcare workers in Belgium (7), Spain 
(8), and Germany (9) (1.6%–9.3%): no major differ-
ence in IgG prevalence was found according to job 
types. In our study, the highest prevalence was ob-
served for healthcare workers in direct contact with 
patients and the lowest for administrative staff 
members. S1/S2 IgG titers were higher in older 
participants and in those who had a previous diag-
nosis of COVID-19. In an assay validation study in 
Boise, Idaho, USA, a seroprevalence of 1.79% was 
reported; older participants had the highest rates 
(4%, >80 years of age).
Higher titers in symptomatic patients (we pre-
sume were healthcare workers given a diagnosis 
304 Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 27, No. 1, January 2021
RESEARCH LETTERS
Figure. Seroprevalence of 
severe acute respiratory 
syndrome coronavirus 2 
antibodies in healthcare 
workers according to tasks 
of participants, Turin, Italy. 
Participants are grouped 
according to direct (black bars) 
or indirect/no contact (gray bars) 
with patients. The difference 
between these 2 groups (7.5% 
vs. 5.2%) is significant (p = 
0.013 by χ2 test). The healthcare 
personnel category includes 
psychologists, nutritionists, 
welfare workers, religious 
assistants, physical therapists, 
and orthoptists.
of COVID-19 according to the local testing 
policy) have been described (https://www.cdc.
gov/coronavirus/2019-ncov/lab/resources/ 
antibody-tests-guidelines.html;  https://www.who. 
int/docs/default-source/coronaviruse/whoin-
houseassays.pdf?sfvrsn=de3a76aa_2). Although a 
shorter time from disease onset might explain 
the lack of antibodies, a lower seroprevalence in 
younger, previously infected healthcare workers 
was unexpected. A total of 3.5% of seropositive par-
ticipants with no previous diagnosis of COVID-19 
had positive PCR results for nasopharyngeal swab 
specimens; this finding might represent late-stage 
infections with low/no infectivity.
Our study has limitations, including incomplete 
coverage of healthcare workers (27% did not respond) 
and lack of complete job description and disease se-
verity for all participants. Some persons did not show 
development of IgG after having COVID-19; thus, 
our study could have missed a subset of previously 
infected persons (10). Despite limitations, our study 
provides noteworthy estimates about the differential 
risk for acquiring SARS-CoV-2 infection by health-
care workers according to their specific job setting in 
a large occupational survey.
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Appendix Figure. Spike protein subunits S1/S2 SARS-CoV-2 antibody arbitrary units according to age for 
healthcare workers, Turin, Italy. Horizontal bars indicate medians, boxes indicate interquartile ranges, whiskers 
indicate 10%–90% percentiles, circles indicate outliers, stars indicate extreme outliers, and dashed horizontal 
lines indicate assay cutoff values (negative: <12 arbitrary units/mL; equivocal: 12–15 arbitrary units/mL; positive: 
>15 arbitrary units/mL). A statistically significant difference in IgG titers according to age was observed (p = 0.001 
by analysis of variance). SARS-CoV-2, severe acute respiratory syndrome coronavirus 2. 
